Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - exemestane -

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - exemestane 25mg - coated tablet - 25 mg - active: exemestane 25mg excipient: crospovidone hydrated silica hypromellose   macrogol 6000 magnesium carbonate magnesium stearate mannitol methyl hydroxybenzoate polysorbate 80 polyvinyl alcohol powdered cellulose simeticone sodium starch glycolate sucrose   titanium dioxide - · the adjuvant treatment of postmenopausal women with oestrogen receptor positive or receptor unknown early breast cancer after initial adjuvant tamoxifen to reduce the risk of recurrence (distant and loco-regional) and contralateral breast cancer · the treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy · the third-line hormonal treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease progressed following treatment with anti-oestrogens and either non-steroidal aromatase inhibitors or progestins.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - exemestane 25mg - film coated tablet - 25 mg - active: exemestane 25mg excipient: colloidal silicon dioxide crospovidone hypromellose e-5 magnesium stearate mannitol microcrystalline cellulose opadry white polysorbate 80 purified water   sodium starch glycolate - · exaccord is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive or receptor unknown early breast cancer after initial adjuvant tamoxifen to reduce the risk of recurrence (distant and loco-regional) and contralateral breast cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - exemestane 25mg;   - film coated tablet - 25 mg - active: exemestane 25mg   excipient: colloidal silicon dioxide crospovidone hypromellose magnesium stearate mannitol microcrystalline cellulose opadry white y-1-7000 polysorbate 80 sodium starch glycolate - mestane is indicated for: · the adjuvant treatment of postmenopausal women with oestrogen receptor positive or receptor unknown early breast cancer after initial adjuvant tamoxifen to reduce the risk of recurrence (distant and loco-regional) and contralateral breast cancer.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - coated tablets - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Ireland - English - HPRA (Health Products Regulatory Authority)

haemato pharm ag - exemestane - coated tablets - 25 milligram - aromatase inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

ips healthcare limited - exemestane - coated tablets - 25 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - exemestane - coated tablet - 25 milligram(s) - aromatase inhibitors; exemestane

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - exemestane - film coated tablet - 25 milligram - exemestane

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - exemestane - film-coated tablet - 25 milligram(s) - aromatase inhibitors; exemestane